Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AKLI

Akili (AKLI) Stock Price, News & Analysis

Akili logo

About Akili Stock (NASDAQ:AKLI)

Advanced Chart

Key Stats

Today's Range
$0.43
$0.43
50-Day Range
$0.42
$0.44
52-Week Range
$0.19
$1.25
Volume
N/A
Average Volume
2.20 million shs
Market Capitalization
$34.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Receive AKLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter.

AKLI Stock News Headlines

Trump’s Bitcoin Reserve is No Accident…
For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.
See More Headlines

AKLI Stock Analysis - Frequently Asked Questions

Akili, Inc. (NASDAQ:AKLI) released its quarterly earnings results on Thursday, May, 11th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.04. The company earned $0.11 million during the quarter. Akili had a negative net margin of 2,492.04% and a negative trailing twelve-month return on equity of 79.93%.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akili investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM), NVIDIA (NVDA), P3 Health Partners (PIII) and uniQure (QURE).

Company Calendar

Last Earnings
5/11/2023
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AKLI
Fax
N/A
Employees
130
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$59.49 million
Net Margins
-2,492.04%
Pretax Margin
-2,489.32%

Debt

Sales & Book Value

Annual Sales
$1.95 million
Price / Cash Flow
N/A
Book Value
$0.75 per share
Price / Book
0.58

Miscellaneous

Free Float
70,776,000
Market Cap
$34.01 million
Optionable
Optionable
Beta
1.72
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:AKLI) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners